Opendata, web and dolomites

ONCOTHERANOSTICS SIGNED

Advanced Theranostic Nanomedicines for Oncology. Development of new combinatorial therapies for primary and metastatic Breast Cancer.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ONCOTHERANOSTICS project word cloud

Explore the words cloud of the ONCOTHERANOSTICS project. It provides you a very rough idea of what is the project "ONCOTHERANOSTICS" about.

theranostics    personalizing    malignancy    reinforcing    effect    therapeutic    2nd    incoming    dr    establishment    multiple    immunotherapy    trained    globally    vivo    outgoing    theranostic    triggers    multifaceted    negative    single    line    treatments    nanomedicine    genetic    primary    completion    mri    downregulation    multidisciplinary    expertise    molecular    mechanisms    genes    diagnostic    nanomedine    transferred    intervention    provides    combining    treatment    cancer    oncotheranostics    triple    monitor    anticipate    surveillance    metastatic    tumoral    host    techniques    organic    personalize    natural    synthesis    breast    training    interplay    despite    health    imaging    death    chemist    escaping    dual    uses    nanoparticle    pacheco    biology    environment    cutting    formulation    rendering    personalized    knocking    choline    kinase    cells    invasively    agent    treat    boosting    cross    combinatorial    strategies    sirna    therapies    tumor    successful    multimodal    care    safer    proposes    purpose    immune    model    competitiveness   

Project "ONCOTHERANOSTICS" data sheet

The following table provides information about the project.

Coordinator
AGENCIA ESTATAL CONSEJO SUPERIOR DEINVESTIGACIONES CIENTIFICAS 

Organization address
address: CALLE SERRANO 117
city: MADRID
postcode: 28006
website: http://www.csic.es

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 257˙191 €
 EC max contribution 257˙191 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-GF
 Starting year 2019
 Duration (year-month-day) from 2019-03-01   to  2022-02-28

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    AGENCIA ESTATAL CONSEJO SUPERIOR DEINVESTIGACIONES CIENTIFICAS ES (MADRID) coordinator 257˙191.00
2    JOHNS HOPKINS UNIVERSITY US (BALTIMORE) partner 0.00

Map

 Project objective

Despite significant advances in recent years, cancer remains the 2nd cause of death globally. Immunotherapy is an exciting new therapeutic approach that triggers natural immune response against cancer cells. Theranostics is an emerging therapeutic intervention, that uses dual (or multiple) purpose nanomedine, combining diagnostic and therapeutic effects within a single multifaceted formulation. ONCOTHERANOSTICS proposes the use of a novel theranostic agent to target key tumoral genes by siRNA and monitor the impact of the downregulation non-invasively in vivo. Specific aims include understanding the interplay between choline kinase and tumor escaping natural immune surveillance, and to develop new combinatorial therapies in a model of primary and metastatic triple negative breast cancer. We anticipate that successful completion of the project will result in significant advances in personalized tumor treatments, rendering safer strategies to treat cancer with a dual effect; boosting natural immune response and knocking down one of the main mechanisms of malignancy. Dr. Pacheco is an organic chemist with expertise in MRI who will be trained (outgoing) in nanoparticle synthesis, non-MRI imaging techniques and advanced molecular biology/genetic approaches. Training will be transferred to the host European institution (incoming) by the establishment of a new research line in the emerging field of Theranostics. ONCOTHERANOSTICS seeks to improve our understanding of cancer and how to personalize treatments, fostering the development of nanomedicine targeting specific genes in a way that can be assessed non-invasively. ONCOTHERANOSTICS provides a multidisciplinary environment for cancer treatment, involving multifaceted nanomedicine, multimodal molecular imaging and molecular biology/genetic approaches. The proposal directly addresses the cross cutting priority of personalizing health and care established by H2020, reinforcing European competitiveness in cancer research.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ONCOTHERANOSTICS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ONCOTHERANOSTICS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

ELOTEQ (2019)

Interfacing Levitated Optomechanics with Superconducting Qubits

Read More  

Catenin-Condensation (2020)

The effect of β-catenin condensation on the Wnt-pathway

Read More  

SSHelectPhagy (2019)

Regulation of Selective autophagy by sulfide through persulfidation of protein targets.

Read More